1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. ADC Market Outlook to 2020
4.1 ADCETRIS
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2020
4.2 Kadcyla
4.2.1 Market Potential
4.2.2 Market Size and Forecasts to 2020
5. ADC Pipeline Analysis
5.1 By Phase
5.2 By Indication
5.3 By Drug
6. Drivers and Challenges
6.1 Drivers
6.1.1 Advances in Linking Technologies Re-Instills Hope in ADC
6.1.2 Efforts towards Patent Protection to Drive ADC Market
6.2 Challenges
6.2.1 Production Hurdles and Cost
6.2.2 Inadequacy of Experienced Manufacturers
6.2.3 Regulatory Challenges
7. Current Status of Potential ADCs in Pipeline
7.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
7.2 Coltuximab Ravtansine/SAR3419 - Immunogen Inc.
7.3 Indatuximab Ravtansine/BT-062 - Biotest
7.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
7.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
7.6 Pinatuzumab Vedotin/RG7593 - Roche Genentech
7.7 Lifastuzumab Vedotin/RG7599 - Roche Genentech
7.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
7.9 Inotuzumab Ozogamicin (CMC-544) - Pfizer
8. Trends and Developments
8.1 ADC at the Forefront to Treat Hematological Malignancies
8.2 ADCs Providing Advantages to Breast Cancer Patients
9. Strategic Collaborations in the ADC Industry
10. Competitive Assessment
10.1 Seattle Genetics
10.2 Roche
10.3 Immunogen, Inc.
10.4 Bayer Healthcare
10.5 Novartis
10.6 Immunomedics
10.7 Agensys, Inc